REPLY : Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Extended Real World Data With Outpatient Dose Titration
- 19 November 2025
- journal article
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (4) , 1111-1112
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Extended Real World Data with Outpatient Dose TitrationMovement Disorders Clinical Practice, 2025
- Subcutaneous foslevodopa/foscarbidopa initiation in a Parkinson’s day-clinic - a suitable setting to ensure treatment efficacy, tolerability and psychosocial adaptionFrontiers in Aging Neuroscience, 2025
- Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant MedicationMovement Disorders Clinical Practice, 2025